KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

TherapeuticsMD (TXMD) Accumulated Depreciation & Amortization (2016 - 2023)

TherapeuticsMD (TXMD) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with $2.5 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Accumulated Depreciation & Amortization changed N/A year-over-year to $2.5 million, compared with a TTM value of $2.5 million through Sep 2023, changed N/A, and an annual FY2022 reading of $2.4 million, up 53.29% over the prior year.
  • Accumulated Depreciation & Amortization was $2.5 million for Q3 2023 at TherapeuticsMD, up from $2.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $2.8 million in Q2 2022 and bottomed at $968824.0 in Q4 2019.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.8 million, with a median of $1.6 million recorded in 2021.
  • The sharpest move saw Accumulated Depreciation & Amortization surged 79.7% in 2020, then dropped 8.39% in 2021.
  • Year by year, Accumulated Depreciation & Amortization stood at $968824.0 in 2019, then soared by 79.7% to $1.7 million in 2020, then decreased by 8.39% to $1.6 million in 2021, then surged by 53.29% to $2.4 million in 2022, then rose by 2.37% to $2.5 million in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for TXMD at $2.5 million in Q3 2023, $2.4 million in Q4 2022, and $2.8 million in Q2 2022.